JP Morgan Chase
KYNB

JP Morgan Chase’s Kyntra Bio KYNB Stock Holding History

JP Morgan Chase’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,000
Closed -$3.71M – 6147
2020
Q4 		$3.71M Buy
+4,000
New +$4.2M ﹤0.01% 3040

Other funds holding KYNB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

JP Morgan Chase's KYNB Position: Q1 2026 in Review

JP Morgan Chase held its Kyntra Bio (KYNB) position steady in Q1 2026 at 12 shares worth $78. The position accounts for ﹤0.01% of the portfolio, ranked #7327.

JP Morgan Chase first reported a position in KYNB in Q4 2014 and has held it in 46 quarters since. The position peaked at $80.3M in Q3 2020. 32 funds tracked by Wall St. Rank hold KYNB as of Q1 2026.

  • JP Morgan Chase held 12 shares of Kyntra Bio worth $78 as of Q1 2026.
  • JP Morgan Chase left its Kyntra Bio share count unchanged in Q1 2026.
  • Kyntra Bio made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7327 holding.
  • JP Morgan Chase first reported a position in Kyntra Bio in Q4 2014 and has held it in 46 quarters since.
  • JP Morgan Chase's Kyntra Bio position peaked at $80.3M in Q3 2020.
  • 32 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.